Search

Your search keyword '"Martin Steins"' showing total 3 results
Start Over Author "Martin Steins" Journal journal of clinical oncology
3 results on '"Martin Steins"'

1. Nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate 017/057 2-y update and exploratory cytokine profile analyses

Author

Oscar Arrieta, Luis Paz-Ares, Scott J. Antonia, Matthew D. Hellmann, Enriqueta Felip, Martin Steins, Jérôme Fayette, Naiyer A. Rizvi, Martin Reck, Kaushal Desai, Leora Horn, Diane Healey, David R. Spigel, Lucio Crinò, Julie R. Brahmer, Neal Ready, Fabrice Barlesi, Wilfried Eberhardt, Ang Li, and Hossein Borghaei

Subjects
0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, business.industry, Cytokine profile, Immune checkpoint inhibitors, Checkmate, Surgery, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Docetaxel, 030220 oncology & carcinogenesis, Internal medicine, medicine, bacteria, In patient, Nivolumab, Previously treated, business, medicine.drug
Abstract

9025Background: Nivo, afully human IgG4 programmed death-1 immune checkpoint inhibitor, is approved in the US for pts with previously treated metastatic NSCLC and in the EU for pretreated locally a...

Published
2016

2. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC)

Author

Scott N. Gettinger, Everett E. Vokes, Oscar Gerardo Arrieta Rodriguez, Fabrice Barlesi, Hossein Borghaei, Friedrich Graf Finckenstein, Laura Q.M. Chow, Marco Angelo Burgio, Christopher T. Harbison, David R. Spigel, Enriqueta Felip, Jérôme Fayette, Martin Steins, Martin Kohlhaeufl, Cecile Dorange, Julie R. Brahmer, Luis Paz-Ares, Neal Ready, Leora Horn, and Esther Holgado

Subjects
Oncology, medicine.medical_specialty, Chemotherapy, Cancer Research, medicine.drug_class, business.industry, medicine.medical_treatment, non-small cell lung cancer (NSCLC), medicine.disease, Tyrosine-kinase inhibitor, law.invention, Surgery, Discontinuation, Docetaxel, Randomized controlled trial, law, Internal medicine, Toxicity, medicine, Nivolumab, business, medicine.drug
Abstract

LBA109 Background: Options for advanced non-SQ NSCLC patients (pts) who progress after platinum-based doublet chemotherapy (PT-DC) are limited, with minimal improvement in overall survival (OS). We report results from a randomized, global phase III study of NIVO, a fully human IgG4 programmed death-1 (PD-1) immune checkpoint inhibitor antibody, vs DOC in pts with advanced non-SQ NSCLC after failure of PT-DC and tyrosine kinase inhibitor, if eligible. Methods: Pts were randomized to NIVO 3 mg/kg Q2W (n=292) or DOC 75 mg/m2 Q3W (n=290) until progression or discontinuation due to toxicity/other reasons. Primary objective was OS; Secondary objectives were investigator-assessed objective response rate (ORR; per RECIST v1.1), progression-free survival (PFS), efficacy by PD-L1 expression, quality of life, and safety. Results: NIVO demonstrated superior OS (HR=0.73; 96% CI: 0.59, 0.89; P=0.00155) and improved ORR (19.2% vs 12.4%; P=0.0235). HR for PFS was 0.92 (95% CI: 0.77, 1.11; P=0.393). PD-L1 expression was associated with benefit from NIVO (Table). In PD-L1+ pts, NIVO showed improved efficacy across all endpoints at predefined 1%, 5%, and 10% cut- points. Grade 3–5 drug-related AEs occurred in 10.5% (30/287) of NIVO and 53.7% (144/268) of DOC pts. No deaths were related to NIVO vs 1 DOC-related death. After discontinuation, 42.1% of NIVO and 49.7% of DOC pts received subsequent systemic therapy. Conclusions: NIVO demonstrated superior OS vs DOC in pts with advanced non-SQ NSCLC after failure of PT-DC. The safety profile of NIVO 3 mg/kg Q2W was favorable vs DOC. NIVO demonstrated survival benefit across histologies in two randomized phase III trials. Clinical trial information: NCT01673867. [Table: see text]

Published
2015

3. Randomized, double-blind, phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor receptor-1 (IGF-1R), for advanced-stage non-small cell lung cancer (NSCLC)

Author

Wilfried Eberhardt, Claus-Peter Schneider, Pasi A. Jänne, Silvia Novello, Carrie Brownstein, S.S. Ramalingam, Martin Steins, L. Liu, David R. Spigel, Martin Reck, Jeffrey A. Engelman, and L. Crinò

Subjects
Cancer Research, medicine.drug_class, business.industry, Medizin, non-small cell lung cancer (NSCLC), Phases of clinical research, Insulin-Like Growth Factor Receptor, medicine.disease, Monoclonal antibody, Placebo, Subclass, law.invention, body regions, Oncology, law, medicine, Recombinant DNA, Cancer research, Erlotinib, business, medicine.drug
Abstract

7527 Background: R1507 (Hoffman LaRoche) is a selective, fully human, recombinant monoclonal antibody (IgG1 subclass) against IGF-1R. Based on strong pre-clinical evidence supporting co-inhibition ...

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results